Vertex Pharmaceuticals Incorporated (VRTX) Financials
PeriodQ2 FY2026
Published
Vertex Pharmaceuticals reported $3.33 billion in total revenue for Q2 FY2026, the quarter ended June 30, 2026, up 12.5% from a year earlier, and net income of $1.1 billion, or $4.31 per diluted share. The growth came from a shift inside the cystic fibrosis franchise rather than from Vertex's biggest medicine: ALYFTREK revenue reached $573.6 million, up 265.8%, while TRIKAFTA/KAFTRIO, still the largest product at $2.50 billion, was down 2.1% as patients transitioned to the newer once-daily therapy. Earnings grew more slowly than revenue, with net income up 6.5%, as commercial spending behind Vertex's non-cystic-fibrosis launches, a higher cost of sales on product mix and a higher effective tax rate all weighed on the bottom line. The results do not reflect Vertex's pending acquisition of Crinetics Pharmaceuticals, agreed in July and expected to close in the third quarter, which the raised full-year revenue guidance also excludes.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $3,333,900,000 | up 12.5% |
| Net income | $1,099,800,000 | up 6.5% |
| Diluted EPS | $4.31 | up 8.0% |
| TRIKAFTA/KAFTRIO revenue | $2,497,200,000 | down 2.1% |
| ALYFTREK revenue | $573,600,000 | up 265.8% |
Company details
| Name | Vertex Pharmaceuticals Inc / Ma |
|---|---|
| Ticker | VRTX |
| CIK | 0000875320 |
| Exchange | Nasdaq |
| State | Massachusetts |
| Incorporation | Massachusetts |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 10-Q, accession 0000875320-26-000259 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-11-03 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Vertex Pharmaceuticals Q2 FY2026
How much revenue did Vertex Pharmaceuticals report in Q2 FY2026?
Vertex Pharmaceuticals reported $3.33 billion in total revenue for Q2 FY2026, the quarter ended June 30, 2026. That is up 12.5% from $2.96 billion in the same quarter a year earlier.
How much did Vertex Pharmaceuticals earn per share in Q2 FY2026?
Vertex Pharmaceuticals earned $4.31 per diluted share in Q2 FY2026, up 8.0% from $3.99 a year earlier, on net income of $1.1 billion.
Is TRIKAFTA revenue still growing for Vertex Pharmaceuticals?
No. TRIKAFTA/KAFTRIO, the largest medicine Vertex Pharmaceuticals sells, generated $2.50 billion in Q2 FY2026, down 2.1% from $2.55 billion a year earlier, as cystic fibrosis patients moved to the newer once-daily ALYFTREK.
How fast is ALYFTREK growing for Vertex Pharmaceuticals?
ALYFTREK, the once-daily cystic fibrosis triple combination Vertex Pharmaceuticals introduced after TRIKAFTA, generated $573.6 million in Q2 FY2026, up 265.8% from $156.8 million a year earlier, making it the main source of the company's revenue growth.
Where can I get Vertex Pharmaceuticals Incorporated (VRTX) financial data in machine-readable form?
Ticker Scout publishes Vertex Pharmaceuticals Incorporated's financial statements as JSON at https://tickerscout.ai/vrtx/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/vrtx/narrative.md and https://tickerscout.ai/vrtx/events.md. Vertex Pharmaceuticals Incorporated's SEC CIK is 0000875320. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Vertex Pharmaceuticals Incorporated (VRTX) next file with the SEC?
Vertex Pharmaceuticals Incorporated (VRTX) is expected to file its next Form 10-Q with the SEC on or around November 3, 2026. That date is a projection rather than a company-announced date: it is derived from Vertex Pharmaceuticals Incorporated's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000875320-26-000259.
Related companies
How this page was built
This page was built from Vertex Pharmaceuticals Incorporated's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names four such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.